B7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature
Cells · 06.08.2025 · 14 (15) · 1209
DOI: 10.3390/cells14151209 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 06.08.2025. Verfasst von Sylwia Mielcarska und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-800…. Hauptthemen laut MEDLINE: B7 Antigens, Neoplasms, Immunotherapy. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 242 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In today’s oncology, immunotherapy arises as a potent complement for conventional cancer treatment, allowing for obtaining better patient outcomes. B7-H3 (CD276) is a member of the B7 protein family, which emerged as an attractive target for the treatment of various tumors. The molecule modulates anti-cancer immune responses, acting through diverse signaling pathways and cell populations. It has been implicated in the pathogenesis of numerous malignancies, including melanoma, gliomas, lung cancer, gynecological cancers, renal cancer, gastrointestinal tumors, and others, fostering the immunosuppressive environment and marking worse prognosis for the patients. B7-H3 targeting therapies, such as monoclonal antibodies, antibody–drug conjugates, and CAR T-cells, present promising results in preclinical studies and are the subject of ongoing clinical trials. CAR-T therapies against B7-H3 have demonstrated utility in malignancies such as melanoma, glioblastoma, prostate cancer, and RCC. Moreover, ADCs targeting B7-H3 exerted cytotoxic effects on glioblastoma, neuroblastoma cells, prostate cancer, and craniopharyngioma models. B7-H3-targeting also delivers promising results in combined therapies, enhancing the response to other immune checkpoint inhibitors and giving hope for the development of approaches with minimized adverse effects. However, the strategies of B7-H3 blocking deliver substantial challenges, such as poorly understood molecular mechanisms behind B7-H3 protumor properties or therapy toxicity. In this review, we discuss B7-H3’s role in modulating immune responses, its significance for various malignancies, and clinical trials evaluating anti-B7-H3 immunotherapeutic strategies, focusing on the clinical potential of the molecule.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 19 Jordana St., 41-800 Zabrze, Poland.
- Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 40-514 Katowice, Poland.
ORCID-Profile: Dariusz Waniczek
Zitieren
APA
Mielcarska, S., Kot, A., Dawidowicz, M., Kula, A., Sobków, P., Kłaczka, D., Waniczek, D., & Świętochowska, E. (2025). B7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature. Cells, 14(15), 1209. https://doi.org/10.3390/cells14151209
Vancouver
Mielcarska S, Kot A, Dawidowicz M, Kula A, Sobków P, Kłaczka D, et al. B7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature. Cells. 2025;14(15):1209. doi:10.3390/cells14151209
BibTeX
@article{Mielcarska2025,
author = {Mielcarska, Sylwia and Kot, Anna and Dawidowicz, Miriam and Kula, Agnieszka and Sobków, Piotr and Kłaczka, Daria and Waniczek, Dariusz and Świętochowska, Elżbieta},
title = {B7-H3 in Cancer Immunotherapy—Prospects and Challenges: A Review of the Literature},
journal = {Cells},
year = {2025},
volume = {14},
number = {15},
pages = {1209},
doi = {10.3390/cells14151209}
}
EUVIMED